In 1995, it was shown that in active lesions of patients with MS there was an increase in IL-1, IL-2, IL-4, IL-10, TNF-α, tumor growth factor-beta (TGF-β), and IFN-γ [11]. This evidence concerns the gene IFNG and myeloid sarcoma.